Lipocine (NASDAQ:LPCN) Upgraded by Wall Street Zen to “Hold” Rating

by · The Markets Daily

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN – Free Report) from a sell rating to a hold rating in a research note released on Sunday.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $15.00 price target (up previously from $7.00) on shares of Lipocine in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.00.

Get Our Latest Stock Report on LPCN

Lipocine Stock Down 0.1%

Lipocine stock opened at $8.66 on Friday. The firm has a fifty day moving average of $7.44 and a 200-day moving average of $4.55. Lipocine has a 52-week low of $2.52 and a 52-week high of $12.37. The firm has a market capitalization of $48.06 million, a P/E ratio of -8.49 and a beta of 0.99.

Hedge Funds Weigh In On Lipocine

Several institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in shares of Lipocine during the third quarter worth approximately $41,000. Jane Street Group LLC acquired a new position in Lipocine during the 4th quarter worth $85,000. Geode Capital Management LLC grew its holdings in Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after acquiring an additional 1,374 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after purchasing an additional 1,300 shares during the last quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

(Get Free Report)

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.

Featured Stories